Alendronate for the treatment of osteoporosis in men.
By E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann and 2 more. New England Journal of Medicine, 2000
915 citations recorded by the source corpus.
Subfields: Oncology, Orthopedics and Sports Medicine
View Paper: https://www.semanticscholar.org/paper/8a67c7bb168c44908bedd46b0d1b891fe9b4eda0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Orthopedics and Sports Medicine
Citations in the corpus
- The decline of androgen levels in elderly men and its clinical and therapeutic implications. (2005, background): “Moreover, for oral alendronate (465) and for daily sc injections of recombinant (1–34)PTH (466), two drugs presently available for treatment of men with low BMD, it has been documented that, combined with calcium and vitamin D supplements, these drugs have beneficial effects on BMD independent of ag”
- UK clinical guideline for the prevention and treatment of osteoporosis (2017, neutral): “bridging studies [73, 80, 85, 88, 98], although reduction in vertebral fractures has also shown in men with oste-”
- Severely suppressed bone turnover: a potential complication of alendronate therapy. (2005, background): “Group B 5 68/F PO 3 E2, Ca, D Sacrum, ischium (3) 3 months (ischium) Yes (8) 6 70/F PO 5 E2, Ca, D Pubic rami (3) 2 yr (pubic rami) Yes (4) 7 67/F POpen 5 E2, Ca, D Bilateral femoral shaft (5) 9 months (left femoral shaft) Yes (5)”
- The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis (2003, methodology): “Kurland et al.(12) also found that endogenous PTH fell by 50% from baseline at 6 months in a group of osteoporotic men treated with 400 IU PTH (1-34) daily (approximately equivalent to 25 g), and was 40% lower after 18 months of therapy (p 0.05 vs. placebo).”
- Bisphosphonates: Mechanism of Action and Role in Clinical Practice (2008, neutral): “33–35 In the Fracture Intervention Trial Long-term Extension, postmenopausal women with low femoral neck BMD (but not necessarily with DXA-defined osteoporosis) were treated with daily alendronate for 5 years and then randomized to receive either alendronate or placebo for an additional 5 years.”